Day: December 13, 2021

NEW YORK, NY, Dec. 13, 2021 (GLOBE NEWSWIRE) — Integral Acquisition Corporation 1 (NASDAQ: INTEU) (the “Company”) announced that, commencing on December 16, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A common stock and warrants included in the units.  No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Class A common stock and warrants that are separated will trade on the NASDAQ Global Market under the symbols “INTE” and “INTEW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “INTEU.”  Each unit consists of one share of Class A common stock of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof...

SUNNYVALE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Ken Xie, Founder, Chairman of the Board and CEO at Fortinet“Fortinet has led the evolution of cybersecurity innovation over the past two decades, and is leading the next-generation of security solutions. The network security market is rapidly expanding from the data center out to the work-from-anywhere edge and to the cloud. We expect our innovative ASIC-supported security fabric platform and converged Security-driven networking approach to uniquely position Fortinet for long-term growth. Taking our place on the Nasdaq-100 Index amongst other category-defining companies is another proofpoint of Fortinet’s successes and future growth opportunities.” News Summary Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated and automated cybersecurity solutions, today announced...

5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 10 of 11 Patients Treated with a Second FT596 Cycle Continue in Ongoing Response, with 3 Patients in Ongoing Complete Response at ≥6 Months Follow-up; Additional 2 Patients Reach 6 Months in Complete Response FT596 Treatment Regimens were Well-tolerated; No Dose-limiting Toxicities, and No Adverse Events of Any Grade of ICANS or GVHD, were Observed; Three Low-grade Adverse Events of CRS Resolved without Intensive Care Treatment Company to Host Virtual Investor Event Tomorrow at 8:00 AM Eastern Time SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics,...

Singapore, Dec. 13, 2021 (GLOBE NEWSWIRE) — 8i Acquisition 2 Corp. (NASDAQ: LAXXU) (the “Company”), a newly organized blank check company incorporated as a British Virgin Islands business company and led by Chief Executive Officer, Meng Dong (James) Tan, today announced that commencing December 14, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares, warrants and rights included in the units. No fractional rights or warrants will be issued upon separation of the units and only whole rights and warrants will trade. The ordinary shares, warrants and rights that are separated will trade on The Nasdaq Global Market (“NASDAQ”) under the symbols “LAX,” “LAXXW,” and “LAXXR,”. Those units not separated will continue to trade on NASDAQ under the...

HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO, TORONTO and ATLANTA, Dec. 13, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML). Data were presented in an oral presentation today at the 2021 American Society of Hematology (ASH) Annual meeting by lead investigator Naval G. Daver, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. HM43239 is an oral, once-daily, highly potent myeloid kinome inhibitor (MKI) designed to target key kinases operative...

SAN JOSE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Heritage Commerce Corp (Nasdaq: HTBK), the holding company (the “Company”) for Heritage Bank of Commerce (the “Bank”), today announced the appointment of Kamran Husain to the Board of Directors (the “Board”) of Heritage Commerce Corp, expanding the Company’s Board to twelve directors from eleven. Mr. Husain will also serve as a member of Board’s Audit Committee and its Personnel and Compensation Committee. Mr. Husain was also appointed to the Heritage Bank of Commerce Board of Directors. “We are delighted to welcome Kamran to the Company’s Board of Directors, and look forward to working with him as we pursue our mission to grow our franchise,” said Jack Conner, Chairman of the Board. “His deep experience in banking and finance, coupled with his extensive leadership skills and insight,...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — Globalink Investment Inc. (Nasdaq: GLLIU) (the “Company” or “Globalink”) today announced that the underwriters of its previously announced public offering of units have exercised their over-allotment option resulting in the issuance of an additional 1,500,000 units.  The units began trading on The Nasdaq Global Market, (“Nasdaq”) under the ticker symbol “GLLIU” on December 7, 2021. Each unit consists of one share of common stock, one redeemable warrant (with each warrant entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share) and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Once the securities comprising...

Meritage Homes appoints Louis E. Caldera to its Board of DirectorsLouis E. CalderaSCOTTSDALE, Ariz., Dec. 13, 2021 (GLOBE NEWSWIRE) — Meritage Homes (NYSE:MTH), a leading U.S. homebuilder, announced the appointment of Louis E. Caldera to its Board of Directors as an independent director. His appointment brings the Board of Directors to a total of 11. The Board plans to consider Mr. Caldera for appointment to one or more board committees over the course of the next several regularly scheduled Board meetings. Mr. Caldera, a private investor and consultant, brings to the Meritage Board a rich background spanning leadership positions in higher education, military, and public service. Mr. Caldera served as Secretary of the Army under the Clinton administration and as Director of the White House Military Office under...

Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative biotech company announces that Mr. David Goren has resigned from the board of directors of the Company with immediate effect, and the board has accepted his resignation. The Company thanks Mr. Goren for his contribution to the Company and wishes him every success in his future endeavors. The directors of Vaxil have commenced a search for an appropriate replacement for Mr. Goren and will submit the candidate for approval by Vaxil’s shareholders at its upcoming annual and special meeting to be held on February 7, 2022. ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers...